Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National Lung Matrix Trial in Non-small Cell Lung Cancer
NCT02664935Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- May 2015
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib, vistusertib, palbociclib, crizotinib, selumetinib in non-small cell lung cancer (NSCLC), sponsored by University of Birmingham. Started May 2015; status: completed.
02
Drugs
fexagratinibvistusertibpalbociclibcrizotinibselumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02664935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664935.